(0.31%) 5 115.89 points
(0.31%) 38 358 points
(0.34%) 15 982 points
(-0.86%) $83.13
(5.77%) $2.03
(0.37%) $2 356.00
(0.48%) $27.67
(4.02%) $959.20
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Quarter results tomorrow
(bmo 2024-04-30)
Expected move: +/- 10.97%
@ $14.92
発行日: 15 2月 2024 @ 05:55
リターン: 4.62%
前回のシグナル: 2月 15 - 04:11
前回のシグナル:
リターン: 1.53 %
Live Chart Being Loaded With Signals
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments...
Stats | |
---|---|
本日の出来高 | 977 749 |
平均出来高 | 904 177 |
時価総額 | 1.99B |
EPS | $0 ( 2024-02-20 ) |
次の収益日 | ( $-0.0300 ) 2024-04-30 |
Last Dividend | $0.400 ( 2020-12-17 ) |
Next Dividend | $0 ( N/A ) |
P/E | -22.30 |
ATR14 | $0.0460 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Tetrault Lynn A. | Sell | 6 112 | Common Stock |
2024-02-23 | Stone Warren | Buy | 42 344 | Stock Option (Right to Buy) |
2024-02-23 | Stone Warren | Buy | 25 330 | Performance Stock Unit |
2024-02-23 | Stone Warren | Buy | 25 329 | Restricted Stock Unit |
2024-02-23 | Olivo Alicia C | Buy | 42 344 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
92.19 |
Last 88 transactions |
Buy: 4 083 000 | Sell: 279 791 |
ボリューム 相関
Neogenomics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Neogenomics Inc 相関 - 通貨/商品
Neogenomics Inc 財務諸表
Annual | 2023 |
収益: | $591.64M |
総利益: | $244.60M (41.34 %) |
EPS: | $-0.700 |
FY | 2023 |
収益: | $591.64M |
総利益: | $244.60M (41.34 %) |
EPS: | $-0.700 |
FY | 2022 |
収益: | $509.73M |
総利益: | $187.90M (36.86 %) |
EPS: | $-1.160 |
FY | 2021 |
収益: | $484.33M |
総利益: | $187.06M (38.62 %) |
EPS: | $-0.0700 |
Financial Reports:
No articles found.
Neogenomics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.400 | 2020-12-17 |
Last Dividend | $0.400 | 2020-12-17 |
Next Dividend | $0 | N/A |
Payout Date | 2020-12-30 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.400 | -- |
Avg. Dividend % Per Year | 0.09% | -- |
Score | 0.55 | -- |
Div. Sustainability Score | 3.17 | |
Div.Growth Potential Score | 0.167 | |
Div. Directional Score | 1.670 | -- |
Year | Amount | Yield |
---|---|---|
2020 | $0.400 | 1.38% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.149 | 1.500 | -2.97 | -4.46 | [0 - 0.5] |
returnOnAssetsTTM | -0.0523 | 1.200 | -1.744 | -2.09 | [0 - 0.3] |
returnOnEquityTTM | -0.0921 | 1.500 | -2.13 | -3.20 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 6.20 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.67 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.56 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.364 | -1.500 | 3.94 | -5.90 | [0 - 0.6] |
interestCoverageTTM | 20.01 | 1.000 | 3.70 | 3.70 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0155 | 2.00 | -0.00517 | -0.0103 | [0 - 30] |
freeCashFlowPerShareTTM | -0.244 | 2.00 | -0.122 | -0.244 | [0 - 20] |
debtEquityRatioTTM | 0.650 | -1.500 | 7.40 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.413 | 1.000 | 6.44 | 6.44 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.174 | 1.000 | -5.48 | -5.48 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.00319 | 1.000 | -1.129 | -1.129 | [0.2 - 2] |
assetTurnoverTTM | 0.352 | 0.800 | -0.987 | -0.790 | [0.5 - 2] |
Total Score | 3.17 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -20.24 | 1.000 | -2.15 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0921 | 2.50 | -1.372 | -3.20 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.244 | 2.00 | -0.0813 | -0.244 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0155 | 2.00 | -0.00517 | -0.0103 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 2.32 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.00330 | 1.000 | -2.58 | 0 | [0.1 - 0.5] |
Total Score | 0.167 |
Neogenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。